Introduction
Gastric cancer (GC) remains a significant global health burden, characterized by high mortality rates and often poor prognosis due to late-stage diagnosis. While traditional research has focused on protein-coding genes, the emergence of non-coding RNAs, particularly circular RNAs (circRNAs), has opened new avenues for understanding cancer biology. circRNAs are unique due to their covalently closed loop structure, which grants them exceptional stability against cellular degradation. This study investigates the role of circular RNA CCDC66 (circCCDC66) in gastric cancer, exploring its potential as a biomarker and its influence on tumor progression.
Methods and Materials
To evaluate the clinical and biological significance of circCCDC66, researchers utilized a multi-faceted approach:
- Clinical Analysis: circCCDC66 expression was measured via quantitative real-time PCR (qRT-PCR) in 70 pairs of gastric cancer tissues and adjacent normal tissues obtained from patients at the First People’s Hospital of Zhenjiang.
- Cellular Models: Human GC cell lines (SGC-7901, HGC-27, MGC-803, BGC-823) and a normal gastric epithelial cell line (GES-1) were used for in vitro studies.
- Functional Assays: The impact of circCCDC66 on cell behavior was assessed through knockdown (siRNA) and overexpression (plasmid) experiments. Key metrics included cell proliferation (colony formation), apoptosis (flow cytometry), and metastatic potential (wound healing and transwell invasion assays).
- In Vivo Validation: A mouse xenograft model was employed to observe the effect of circCCDC66 silencing on actual tumor growth in a living organism.
- Mechanistic Studies: Western blotting was used to analyze the expression of proteins related to the Epithelial-Mesenchymal Transition (EMT) and key signaling pathways.
Results
Upregulation of circCCDC66 in Gastric Cancer
The study found that circCCDC66 is significantly overexpressed in gastric cancer. Specifically, it was upregulated in 68.5% (48/70) of the clinical GC tissue samples compared to adjacent normal tissues. This elevated expression was not limited to tissues; it was also consistently observed across multiple gastric cancer cell lines compared to the normal GES-1 control line.
Importantly, higher levels of circCCDC66 were significantly correlated with more advanced tumor stages and the presence of lymphatic metastasis, suggesting that its expression level could serve as a prognostic indicator.
Impact on Tumor Growth and Metastasis
Functional assays revealed that circCCDC66 acts as a potent oncogene. Knocking down circCCDC66 significantly inhibited the proliferation, migration, and invasion of GC cells while simultaneously inducing apoptosis. Conversely, overexpressing circCCDC66 promoted these malignant phenotypes. These findings were further validated in vivo, where tumors derived from circCCDC66-silenced cells were significantly smaller in both volume and weight compared to control groups.
Mechanistic Insights: The c-Myc and TGF-β Axis
The study elucidated that circCCDC66 drives progression by activating two critical oncogenic pathways:
- c-Myc Pathway: circCCDC66 promotes the activation of c-Myc, a master regulator of cell growth and metabolism.
- TGF-β Signaling and EMT: circCCDC66 triggers the TGF-β pathway, which in turn facilitates the Epithelial-Mesenchymal Transition (EMT). During EMT, cells lose epithelial markers like E-cadherin and gain mesenchymal markers like Vimentin and N-cadherin, significantly increasing their mobility and invasive capacity.
Rescue experiments confirmed these links: when circCCDC66 was overexpressed alongside the inhibition of either c-Myc or TGF-β, the cancer-promoting effects were largely neutralized. This demonstrates that circCCDC66 relies on these pathways to exert its oncogenic influence.
Conclusion
This research identifies circCCDC66 as a key player in gastric cancer pathogenesis. By co-activating the c-Myc and TGF-β signaling pathways, circCCDC66 promotes cell survival, rapid proliferation, and metastatic spread. Given its stability and clinical correlation with disease severity, circCCDC66 represents a promising candidate for a diagnostic biomarker and a potential target for future therapeutic interventions in gastric cancer.
Summary updated